NSE: INDGN | BSE: 544172

Turnaround Potential

Download real time

590.15 -16.95 (-2.79%)

42.55% Gain from 52W Low

220.4K NSE+BSE Volume

NSE 08 Oct, 2026 2:18 PM (IST)

14,217.5

Market Cap

High in industry

Beta 1Year

Very Low volatility

Indegene Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for INDGN, BSE:544172 Indegene Ltd.

Search Inside the pdf :

Indegene Ltd.

25 Sep 2026

590.15

-2.79%

A life sciences workflow outsourcing growth story - Indegene, founded in 1998, is a digital-first commercialization partner focused on the global life sciences industry. It serves 20/20 top biopharma companies and operates across 80+ markets through 17+...

Indegene Ltd. is trading above its 200 day SMA of 517.1

Indegene Ltd.

24 Sep 2026

590.15

-2.79%

Life science and pharma opex outsourcing a key tailwind

Buy: Indegene Ltd.

Recommendation Target

Motilal Oswal

Global life science and pharma companies prefer to onboard external agencies like Indegene to reduce operational costs, accelerate go-tomarket, access specialized global talent, and manage the spike in content volume during the drug launch and drop during periods with no updates.

Indegene Ltd. is trading above its 200 day SMA of 517.1

Indegene Ltd.

24 Sep 2026

590.15

-2.79%

Initiating Coverage:Indegene

Buy: Indegene Ltd.

Axis Direct

We initiate coverage on Indegene Ltd. with a BUY recommendation and a target price of Rs 705/share, implying ~18% upside from the CMP.

Indegene Ltd. is trading above its 200 day SMA of 517.1

Indegene Ltd.

31 Jul 2026

590.15

-2.79%

Performance in line with expectations; FY27 expected to be better than FY26

Neutral: Indegene Ltd.

Target

Motilal Oswal

Indegene’s 1QFY27 revenue rose 2.5% QoQ and 26.5% YoY to USD113m (in line with our estimate), while INR revenue grew 6.0% QoQ and 39.7% YoY to INR10.6b (MOFSL est: INR10.4b).

Indegene Ltd. is trading below its 30 day SMA of 592.0

Indegene Ltd.

29 Jul 2026

590.15

-2.79%

Indegene: Initiating Coverage

Buy: Indegene Ltd.

IDBI Capital

market depends on pharma commercialization, medical affairs and regulatory outsourcing with an estimation at over USD 40bn by 2033, yet Indegene's FY26 revenue represents well under 0.2% of this opportunity. Rising drug development costs, patent cliffs, and increasing outsourcing...

ICICI Direct released a Buy report for Indegene Ltd. with a price target of 750.0 on 25 Sep, 2026.

Indegene Ltd.

02 May 2026

590.15

-2.79%

Robust growth with improving life sciences demand outlook

Buy: Indegene Ltd.

ICICI Securities Limited

Indegene showed robust revenue growth performance with broad-based traction across ECS/EMS. Issues in top client seem to have abated for now.

Indegene Ltd. is trading above its 200 day SMA of 517.1

Indegene Ltd.

02 May 2026

590.15

-2.79%

Performance in line; FY27 likely to be better than FY26

Neutral: Indegene Ltd.

Target

Motilal Oswal

Indegene’s 4QFY26 revenue rose to 6.5% QoQ to INR10b (in line with our estimate), while Ex-BioPharm revenue growth stood at 5.6%.

Indegene Ltd. is trading above its 200 day SMA of 517.1

Indegene Ltd.

31 Jan 2026

590.15

-2.79%

Acquisition drives growth with steady organic performance

Neutral: Indegene Ltd.

Motilal Oswal

Indegene’s 3QFY26 USD revenue rose 15.1% QoQ, aided by the BioPharm acquisition, while organic USD revenue growth stood at 4% QoQ (below our estimate).

Indegene has gained 27.01% in the last 6 Months

Indegene Ltd.

10 Jul 2024

590.15

-2.79%

Indegene Limited - Revolutionizing Life Sciences' Marketing Way

Buy: Indegene Ltd.

Monarch Networth Capital Limited

Indegene has gained 27.01% in the last 6 Months

Indegene Ltd.

03 May 2024

590.15

-2.79%

IPO Note - Indegene Limited 06052024

IPO Note: Indegene Ltd.

HDFC Securities

IPO Note - Indegene Limited Indegene Limited (IL) provides digital-led commercialization services for the life sciences industry, including biopharmaceutical, emerging biotech and medical devices companies, that assist them with drug development and clinical trials, regulatory submissions, pharmacovigilance and complaints management, and the sales and marketing of their products